Lipid nanoparticles (LNPs) for in vivo RNA delivery and their breakthrough technology for future applications
RNA therapeutics show a significant breakthrough for the treatment of otherwise incurable
diseases and genetic disorders by regulating disease-related gene expression. The …
diseases and genetic disorders by regulating disease-related gene expression. The …
Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery
A new methodology termed selective organ targeting (SORT) was recently developed that
enables controllable delivery of nucleic acids to target tissues. SORT lipid nanoparticles …
enables controllable delivery of nucleic acids to target tissues. SORT lipid nanoparticles …
mRNA-based vaccines and therapeutics: An in-depth survey of current and upcoming clinical applications
YS Wang, M Kumari, GH Chen, MH Hong… - Journal of Biomedical …, 2023 - Springer
Abstract mRNA-based drugs have tremendous potential as clinical treatments, however, a
major challenge in realizing this drug class will promise to develop methods for safely …
major challenge in realizing this drug class will promise to develop methods for safely …
Chemically modified platforms for better RNA therapeutics
RNA-based therapies have catalyzed a revolutionary transformation in the biomedical
landscape, offering unprecedented potential in disease prevention and treatment. However …
landscape, offering unprecedented potential in disease prevention and treatment. However …
[HTML][HTML] The mixing method used to formulate lipid nanoparticles affects mRNA delivery efficacy and organ tropism
Abstract mRNA is a versatile drug molecule with therapeutic applications ranging from
protein replacement therapies to in vivo gene engineering. mRNA delivery is often …
protein replacement therapies to in vivo gene engineering. mRNA delivery is often …
CRISPR/Cas9 genome editing for tissue‐specific in vivo targeting: nanomaterials and translational perspective
Clustered randomly interspaced short palindromic repeats (CRISPRs) and its associated
endonuclease protein, ie, Cas9, have been discovered as an immune system in bacteria …
endonuclease protein, ie, Cas9, have been discovered as an immune system in bacteria …
[HTML][HTML] LNP-mediated delivery of CRISPR RNP for wide-spread in vivo genome editing in mouse cornea
SZM Mohanna, D Djaksigulova, AM Hill… - Journal of Controlled …, 2022 - Elsevier
Abstract CRISPR/Cas9-based genome-editing therapies are poised to change the clinical
outcome for many diseases with validated therapeutic targets awaiting an appropriate …
outcome for many diseases with validated therapeutic targets awaiting an appropriate …
[HTML][HTML] Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs
Lipid nanoparticle (LNP)-based drug delivery systems have become the most clinically
advanced non-viral delivery technology. LNPs can encapsulate and deliver a wide variety of …
advanced non-viral delivery technology. LNPs can encapsulate and deliver a wide variety of …
[HTML][HTML] Viral and non-viral systems to deliver gene therapeutics to clinical targets
M Taghdiri, C Mussolino - International Journal of Molecular Sciences, 2024 - mdpi.com
Clustered regularly interspersed short palindromic repeats (CRISPR)/CRISPR-associated
protein 9 (Cas9) technology has revolutionized the field of gene therapy as it has enabled …
protein 9 (Cas9) technology has revolutionized the field of gene therapy as it has enabled …
In vivo delivery of CRISPR-Cas9 genome editing components for therapeutic applications
Since its mechanism discovery in 2012 and the first application for mammalian genome
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …
editing in 2013, CRISPR-Cas9 has revolutionized the genome engineering field and created …